110 related articles for article (PubMed ID: 9232213)
1. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
[TBL] [Abstract][Full Text] [Related]
2. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
Katzman MA; Duffin J; Shlik J; Bradwejn J
Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
[TBL] [Abstract][Full Text] [Related]
3. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
[TBL] [Abstract][Full Text] [Related]
4. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
Schruers K; Caycedo N; Overbeek T; Büchold H; Bourin M; Griez E
Eur Neuropsychopharmacol; 2000 Sep; 10(5):419-21. PubMed ID: 10974616
[TBL] [Abstract][Full Text] [Related]
6. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
7. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
8. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J
Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299
[TBL] [Abstract][Full Text] [Related]
9. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
Kronenberg G; Schredl M; Fiedler K; Heuser I
Depress Anxiety; 2001; 14(2):141-4. PubMed ID: 11668667
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.
Koszycki D; Bradwejn J; Bourin M
Eur Neuropsychopharmacol; 1991 May; 1(2):137-41. PubMed ID: 1821703
[TBL] [Abstract][Full Text] [Related]
12. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
13. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
14. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.
Gunnarsson T; Mahoney C; Shlik J; Bradwejn J; Knott V
Pharmacopsychiatry; 2003 Sep; 36(5):181-6. PubMed ID: 14571352
[TBL] [Abstract][Full Text] [Related]
16. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
17. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
[TBL] [Abstract][Full Text] [Related]
18. Effect of aging on cholecystokinin-induced panic.
Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
[TBL] [Abstract][Full Text] [Related]
19. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
Bradwejn J; Koszycki D; Meterissian G
Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
